Hemostemix Inc. Stock Toronto S.E.
Stocks
CA4236943060
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Toronto S.E.
2013-03-06
|
5-day change | 1st Jan Change | ||
| 0.3750 CAD | -46.43% |
|
-.--% | - |
| 07-31 | Hemostemix Raises C$322,250 From Second Tranche of Private Placement | MT |
| 07-08 | Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain | MT |
| Market Cap | 12.86M 9.23M 8M 7.49M 6.83M 880M 13.07M 87.81M 34.4M 441M 34.66M 33.9M 1.47B | P/E 2024 |
-4.36x | P/E 2025 | -3.12x |
|---|---|---|---|---|---|
| Enterprise Value | 15.72M 11.28M 9.78M 9.15M 8.35M 1.08B 15.98M 107M 42.06M 539M 42.37M 41.45M 1.8B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
82.86% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -46.43% |
| Manager | Title | Age | Since |
|---|---|---|---|
Thomas Smeenk
CEO | Chief Executive Officer | - | 2020-02-09 |
Christina Wu
DFI | Director of Finance/CFO | - | 2020-03-04 |
Fraser Henderson
CTO | Chief Tech/Sci/R&D Officer | - | 2021-10-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Smeenk
BRD | Director/Board Member | - | 2019-11-25 |
Ronnie Hershmann
BRD | Director/Board Member | 67 | 2020-02-08 |
Loran Swanberg
BRD | Director/Board Member | - | 2020-04-07 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -46.43% | -.--% | - | - | 9.23M | |
| -0.73% | +12.52% | +74.33% | +102.34% | 70.51B | |
| +1.60% | +1.66% | +37.76% | +66.48% | 54.05B | |
| +1.46% | +35.83% | +10.25% | +503.14% | 28.95B | |
| -0.61% | +12.95% | +53.77% | +5.42% | 24.05B | |
| +0.66% | +1.25% | -15.92% | -13.13% | 23.31B | |
| -1.37% | +18.52% | +255.24% | +464.53% | 18.67B | |
| +2.21% | +7.66% | +47.18% | -19.64% | 18.37B | |
| 0.00% | +9.69% | +31.01% | +584.59% | 16.1B | |
| +0.28% | -9.56% | +35.13% | +138.40% | 12.72B | |
| Average | -4.29% | +9.21% | +58.75% | +203.57% | 29.64B | |
| Weighted average by Cap. | +0.36% | +10.12% | +56.53% | +167.52% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -2.62M -1.88M -1.63M -1.52M -1.39M -179M -2.66M -17.87M -7M -89.67M -7.05M -6.9M -299M | -4.71M -3.38M -2.93M -2.75M -2.51M -323M -4.79M -32.19M -12.61M -162M -12.71M -12.43M -539M |
| Net Debt | 4.23M 3.04M 2.63M 2.46M 2.25M 290M 4.3M 28.89M 11.32M 145M 11.4M 11.16M 484M | 2.86M 2.05M 1.78M 1.67M 1.52M 196M 2.91M 19.54M 7.65M 98.05M 7.71M 7.54M 327M |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
